Develops certepetide, an investigational drug intended to help anti-cancer medicines enter solid tumors, for pharmaceutical developers and research collaborators.
10-K for FY2024, filed Mar 12, 2026Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the…View ↗
To address the tumor stroma’s role as a key impediment to effective treatment, we make use of the C-end rule (“CendR”) active transport…View ↗
Our investigational drug candidate from the CendR Platform®, certepetide, holds broader potential to be combined as a co-administration…View ↗
Pharmaceutical partners pay Lisata upfront fees for licenses; its Qilu agreement also provided for milestone payments and royalties on licensed-product sales.
10-K for FY2024, filed Mar 12, 2026
$170K
10-K for FY2024, filed Mar 12, 2026
$170K ↗
Pharmaceutical partners license certepetide rights from Lisata; past agreements included Qilu in Greater China and Kuva under an exclusive license and collaboration agreement.
10-K for FY2024, filed Mar 12, 2026
No. It lost $16.6M in FY2025.
8-K, filed Sep 17, 2026
Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and…View ↗
8-K, filed Jul 24, 2026
As a result of the Termination, Parent is obligated under the Merger Agreement to pay the Company a termination fee of $2,000,000. In…View ↗
From cell therapies to certepetide
The older report centered on patient-derived cell therapies for ischemic diseases; the latest centers on certepetide, a peptide intended to help anti-cancer drugs enter solid tumors.
10-K for FY2021, filed Mar 22, 2022 10-K for FY2024, filed Mar 12, 2026
Loading...